

**DISCLOSURE STATEMENT PURSUANT TO
THE PINK BASIC DISCLOSURE GUIDELINES**

STRATEGIC ASSET LEASING, INC.

A Wyoming Corporation

13576 Walnut Street

Omaha, NE 68144

(Company's Address)

(402) 239 5556

(Company's telephone number)

www.anewmeds.com

(Company's Website)

joseph@anewmeds.com

(Company's email)

7371 – Computer Programming Services

(Company's SIC Code)

QUARTERLY REPORT

For the Period Ending March 31, 2023

(the "Reporting Period")

Outstanding Shares

As of May 15, 2023, the number of shares outstanding of our Common Stock was:

1,044,861,360 shares

As of December 31, 2022, the Most Recent Fiscal Year End Reporting Period, the number of shares outstanding of our Common Stock was:

1,044,861,360 shares

Shell Status

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes:

No:

Indicate by check mark whether the company's shell company status has changed since the previous reporting period:

Yes:

No:

Change in Control

Indicate by check mark whether a Change in Control of the company has occurred over this reporting period:

Yes:

No:

Item 1. Name of the issuer and its predecessor (if any).

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Strategic Asset Leasing Inc. from 10/02/2014 to present.
Mammoth Energy Group, Inc. from 05/22/2006 to 10/02/2014.
Vision Dynamics Inc. from 02/27/2006 to 05/22/2006.
Technign Corp. from 08/02/2004 to 02/27/2006.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g., active, default, inactive):

The company was organized in Nevada on 08/02/2004 and re-domiciled to Wyoming on March 5 2013. The company's standing is active in the state of Wyoming.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

13576 Walnut Street, Omaha, NE 68144

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address:

Has the Company or any of its predecessors ever been in bankruptcy, receivership, or other similar proceeding in the past five years?

Yes:

No:

If Yes, provide additional details below:

Not applicable

Item 2. Security Information.

Transfer Agent:

Transfer Online, Inc.
512 SE Salmon St.,
Portland, OR 97214
Contact: Carolyn Hall
Phone: (503) 227-2950
Email: info@transferonline.com

Publicly Quoted or Traded Securities:

Trading Symbol:	LEAS
Exact title and class of securities outstanding:	Common Stock
CUSIP:	86270P1063
Par or Stated Value:	\$0.0001 par value
Total Shares Authorized:	1,500,000,000 as of May 15, 2023
Total Shares Outstanding:	1,044,861,360 as of May 15, 2023
Total number of shareholders of record:	33 as of May 15, 2023.

Other classes of authorized or outstanding equity securities:

Trading Symbol:	None
Exact title and class of securities outstanding:	Series B Preferred Stock
CUSIP:	None
Par or Stated Value:	\$0.001 par value
Total Shares Authorized:	500,000 as of May 15, 2023
Total Shares Outstanding:	405,250 as of May 15, 2023
Total number of shareholders of record:	46 as of May 15, 2023.

Trading Symbol:	None
Exact title and class of securities outstanding:	Series C Preferred Stock
CUSIP:	None
Par or Stated Value:	\$0.0001 par value
Total Shares Authorized:	5,000,000 as of May 15, 2023
Total Shares Outstanding:	1,000,000 as of May 15, 2023
Total number of shareholders of record:	1 as of May 15, 2023.

Security Description:

The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. The below information is for each class of the company's equity securities, as applicable:

1. For common equity, describe any dividend, voting and preemption rights.

The holders of our Class A common stock are entitled to receive notice of and attend any meeting of the shareholders of the Corporation and shall be entitled to one vote per share on all matters submitted to a vote of the stockholders. There are no other rights.

2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.

The company is authorized to issue 1,000,000 Class "C" preferred stock at any time issue in one or more series, each series to consist of such number of shares before their issuance, be determined by resolution of the board of directors. The directors of the Corporation may by ordinary resolution, state the designation, rights, privileges, restrictions and conditions attaching to the Class "C" preferred of any series including dividends, redemption or purchase price, voting rights, conversion rights or any other provision. On October 15, 2021, the Company designated 500,000 shares of Series B convertible preferred stock "Series B preferred stock". The holders of each share of the Series B preferred stock shall be entitled to receive dividends declared by the Board of Directors and conversion to 100 shares of the Company's common stock. In the event of a reverse common stock split, there will be no adjustment to the conversion of Series B preferred stock into shares of the Company's common stock.

- A. Describe any other material rights of common or preferred stockholders.

In the event of a reverse common stock split, there will be no adjustment to the conversion of Series B preferred stock into shares of the Company's common stock.

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

Item 3. Issuance History.

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes in the Number of Outstanding Shares.

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: (If yes, you must complete the table below)

Opening Balance: Common: 0 (1) Series C Preferred: -0-									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at issuance	Were the shares issued at a discount to market price at the time of issuance? Yes or No	Individual/Entity Shares were issued to. *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g., for cash or debit conversion) OR Nature of Services Provided (if applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
11/1/2021	New Issuance	1,044,861,360	Common	1,266,900	No	Various	Issued upon Reverse Acquisition (1)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000,000	Series C Preferred	1,280,000	No	Joseph Sinkule	Acquired with Reverse Acquisition (2)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Amnon Mandelbaum	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	17,000	Series B Preferred	21,760	No	Amnon Mandelbaum SEP IRA (Amnon Mandelbaum is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	13,704	Series B Preferred	17,541	No	Amnon Mandelbaum Sunrise Securities (Amnon Mandelbaum is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	10,000	Series B Preferred	12,800	No	Amram Aharoni	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	20,000	Series B Preferred	25,600	No	Ari Ortner	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	10,000	Series B Preferred	12,800	No	Armadillo Ventures, LLC (Joshua Stein is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	5,000	Series B Preferred	6,400	No	Benrose Investments Corp. (Peter Peterburg is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)

11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	Bonnie Robbins	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	Bruce F. Mackler	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,399	Series B Preferred	4,351	No	Chaim Lazarus	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	Christopher Smith	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	5,000	Series B Preferred	6,400	No	CTM Advisory Ltd. (Shawn Mesaros is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	Deirdre Tessman	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	129,501	Series B Preferred	165,761	No	Dr. Joseph Sinkule	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	15,000	Series B Preferred	19,200	No	Dr. Shalom Hirschman	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,219	Series B Preferred	4,121	No	Estery Giloz-Ran	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	10,000	Series B Preferred	12,800	No	Gibralt Capital US, Inc. (Ryan Chan is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,399	Series B Preferred	4,351	No	Haama Ltd (Yaniv Vazan is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	James W Self	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	2,500	Series B Preferred	3,200	No	JIF Holdings (Isaac Fattal is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	250	Series B Preferred	320	No	Johannes P.M. van der Linde	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	John J. Grous	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,000	Series B Preferred	3,840	No	Jon McGarity	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,399	Series B Preferred	4,351	No	Joseph Safra	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Keith Lim	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	50	Series B Preferred	64	No	Marcia Kucher	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	30,000	Series B Preferred	38,400	No	Miguel Chillion Rodriguez	Reverse Acquisition (3)	Restricted	Section 4(a) (2)

11/1/2021	New Issuance	2,755	Series B Preferred	3,526	No	Nathan Low	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,342	Series B Preferred	4,278	No	NLBIDIT 2010 Enterprises LLC (Samir Masri is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	10,000	Series B Preferred	12,800	No	Peter Moriarty	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Phil Fragasso	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	3,100	Series B Preferred	3,968	No	Phil Lavin	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	1,000	Series B Preferred	1,280	No	Rita Kelley Reiter	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	5,899	Series B Preferred	7,551	No	Riverside Claims Investments, LLC (Neal & Elliot Herskowitz is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	2,813	Series B Preferred	3,600	No	Robert Fuchs	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	33,500	Series B Preferred	42,880	No	Sam Zentman	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	16,750	Series B Preferred	21,440	No	Eli Schlissfeld	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	10,000	Series B Preferred	12,800	No	Shalom Hirschman	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	4,719	Series B Preferred	6,041	No	Shaul Eyal	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Stephen Schmidt	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	5,000	Series B Preferred	6,400	No	Sunrise Charitable Foundation (Nathan Low is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Tam Jackson	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	500	Series B Preferred	640	No	Wan Kar Yue (Patrick Wan is the control person)	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	2,950	Series B Preferred	3,776	No	Yaniv Vazan	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
11/1/2021	New Issuance	5,000	Series B Preferred	6,400	No	Yehoshua Abramovich	Reverse Acquisition (3)	Restricted	Section 4(a) (2)

11/1/2021	New Issuance	5,000	Series B Preferred	6,400	No	Yehuda Harats	Reverse Acquisition (3)	Restricted	Section 4(a) (2)
Shares Outstanding on March 31, 2023 (4)	Ending Balance: Common: 1,044,861,360 Series B Preferred: 405,250 Series C Preferred: 1,000,000								

The below space provides any additional details, including footnotes to the table above:

1. On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp (“ANEW”), including the wholly owned subsidiary ANEW Oncology, Inc. The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, ANEW’s assets, liabilities and results of operations became the historical financial statements of the Company. The 1,044,861,360 outstanding shares of Company’s common stock prior to the Agreement and Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.
2. On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp (“ANEW”), including the wholly owned subsidiary ANEW Oncology, Inc. The Agreement and Plan of Merger between the Company and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, ANEW’s assets, liabilities and results of operations became the historical financial statements of the Company. The 1,000,000 outstanding shares of Company’s series B preferred stock prior to the Agreement and Plan of Merger agreement, were considered to be acquired upon the reverse acquisition.
3. On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp (“ANEW”), including the wholly owned subsidiary ANEW Oncology, Inc., whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company’s Series B preferred stock, par value \$.001 per share. On November 1, 2021, the total ANEW stock issued and outstanding was 40,525,000 shares which was converted into 405,250 shares of the Company’s Series B preferred stock.
4. The following shares were not issued as of March 31, 2023:
 - On February 21, 2022, we entered into a Stock Purchase Agreement with an individual to sell 1,666,667 shares of the Company’s common stock for \$250,000 or \$0.15 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of March 31, 2023. The shares have not been issued to the individual on May 15, 2023.

- On September 12, 2022, we entered into a Stock Purchase Agreement with an individual to sell 2,500,000 shares of the Company’s common stock for \$500,000 or \$0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of March 31, 2023. The shares have not been issued to the individual on May 15, 2023.

B. Debt Securities, including Promissory and Convertible Notes.

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer’s equity securities:

No: Yes: (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g., Loan, Services, etc.)
August 1, 2022	1,347,518	1,347,518	-0-	June 30, 2023	N/A	Encore Pharmaceuticals Investor LLC (Joel Schreiber is the control person)	Loan

The below space provides any additional details, including footnotes to the table above:

None

Item 4. Issuer’s Business, Products and Services.

The purpose of this section is to provide a clear description of the issuer’s current operations. In answering this item, please include the following:

The company, Strategic Asset Leasing or “LEAS” was originally organized in Nevada on August 2, 2004 and re-domiciled in Wyoming on March 5, 2013.

On November 1, 2021, the Company executed an Agreement and Plan of Merger with ANEW Acquisition Corp (“ANEW”), including the wholly own subsidiary ANEW Oncology, Inc. ANEW, whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company’s Series B preferred stock, par value \$.001 per share. On November 1, 2021, the total ANEW stock issued and outstanding was aggregate of 40,525,000 shares which was converted into an aggregate of 405,250 shares of the Company’s Series B preferred stock.

The Agreement and Plan of Merger between LEAS and ANEW was treated as a reverse acquisition for financial statement reporting purposes. Accordingly, ANEW’s assets, liabilities and results of operations became the historical financial statements of the Company.

The Company's name will be changed to ANEW MEDICAL, INC. The 1,044,861,360 outstanding shares of Company's common stock prior to the Agreement and Plan of Merger agreement, were considered to be shares issued upon the reverse acquisition.

Also on November 1, 2021, the shareholders of Strategic Asset Leasing, Inc., approved a name change and approved a 1-for-2500 reverse split. On April 19, 2022, the Company filed an Articles of Amendment with the State of Wyoming, changing its name to "ANEW MEDICAL, INC.." and requested the contemplated 1-for-2,500 reverse split. During January 2022 and in accordance with SEC Rule 10b-17 and FINRA Rule 6490, the Company submitted documents and other information to FINRA in furtherance of pursuing and obtaining approval of the subject reverse stock split and name change. The Company must submit additional documents requested by, and necessary to obtain approval of, FINRA in connection with the subject reverse stock split and name change. As of May 15, 2023, the reverse split and name change have not been declared effective.

On February 21, 2022, we entered into a Stock Purchase Agreement with an individual to sell 1,666,667 shares of the Company's common stock for \$250,000 or \$0.15 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of May 15, 2023. The shares have not been issued to the individual at May 15, 2023.

On September 12, 2022, we entered into a Stock Purchase Agreement with an individual to sell 2,000,000 shares of the Company's common stock for \$500,000 or \$0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of May 15, 2023. The shares have not been issued to the individual at May 15, 2023.

Our Business

Anew Acquisition Corp. ("ANEW" or the "Company") was formed to develop essential medicines for the treatment of chronic diseases – cancer, cardiovascular, muscle, skin, and neurodegenerative disorders. There are currently two platform technologies managed by the ANEW team – a "generics" portfolio of drugs and biosimilar biologics selling (1). hard-to-source, difficult to find generic drugs and off-patent biologic therapies, and (2). proprietary", patented technology platforms that include a library of melanocortin receptor-binding molecules, an invitro diagnostic for neurodegenerative diseases, and a gene therapy platform that uses a gene therapy approach to produce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases and other diseases of aging.

Acquisition of Licenses and Assets

Generics and Biosimilars

On September 12, 2022 ANEW acquired five market-approved anti-cancer drugs approved for sale in Germany for \$1,386,766. The Market Authorizations (MA's) are for four of the drugs that comprise the "FOLFOX" and "FOLFIRI" multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. These drugs have previously been the subject of drug shortages and rationing in the past, so we are able to provide an alternative, high quality source of these product was important to us. Having a European manufacturing source for each of the five MA's was also important to the management.

We will combine the generic oncology drugs and additional drug assets with a portfolio of biosimilar biologics also used in the treatment of cancer, and then grow the business with more additions to the portfolio. Initiating marketing and sales in Europe and then migrating the dossier to the US allows us time to build a reliable business franchise and gain name recognition both in Europe and then the US, the two major global pharmaceutical markets. Our pricing of these life-saving medicines is ‘Cost Plus’, meaning the cost to produce these goods and a small margin needed to sell and distribute the drugs. The prices of our products are, therefore, affordable even in this era of significantly increased energy prices in Europe. Our biosimilar biologics will have higher margins as we will invest in Phase 3 studies and market approval expenses for each of those agents, but the strategy is still straightforward.

The Company’s two platforms – generics and patented, proprietary molecules – provides the Company “multiple shots-at-the-goal”, in that we consider generics to be a low risk/near-term for commercialization, and the patented, early-stage programs to be a higher risk/longer-term” commercialization opportunity to potential investors. ANEW licensed several off-patent recombinant antibodies with known therapeutic activity and a known market in treating cancer, autoimmune diseases, and vascular (eye) diseases, and these product candidates require the completion of a Phase 3 pivotal study. If the clinical endpoints of the Phase 3 study are met, they can be approved for marketing in the US and Europe (the major pharmaceutical markets) in three-to-four years from the start of the clinical Phase 3 study. The antibodies have been developed by our corporate partner, Reliance Life Sciences Pvt. Ltd (“RLS”) of Navi Mumbai, India, and the products are already approved for marketing in several countries outside of the US and EU markets, which are ANEW’s exclusively licensed territories.

The Company has recently licensed a melanocortin receptor-binding library of patented peptide molecules similar to those commercialized by Clinuvel and Palatin corporations. The gamma-melanocortins are improved versions of the alpha-melanocortins that are used to treat a variety of skin, intestinal, cardiovascular, and neurologic diseases. The Company’s proprietary diagnostic and gene therapy platform and intellectual property exclusively licensed from a key research institution in Barcelona, Spain (Universitat Autonomus de Barcelona or “UAB”) has shown in several different animal models to have the potential to slow or stop the progression of Alzheimer’s Disease, amyotrophic lateral sclerosis (ALS), and other neurologic disorders of the brain and body in these animals. These “early stage” proprietary product candidates – gamma-melanocortins and secreted Klotho diagnostic, proteins and genes – are not approved in any market, so the Company will have the next 4-5 years to produce lead candidates, do clinical Phase 2 and Phase 3 testing of the candidates, validate their use in clinical trials, and obtain regulatory approval in the major markets around the world. Thus, the melanocortin receptor program and the cell and gene therapy approach at treating age-related diseases (brain cognition, cardiovascular disease, chronic kidney disease, osteoporosis, etc.) are “very high risk” programs, but the products may have a tremendous human impact and a tremendous market potential worldwide.

On January 27, 2023, the Company signed a License Agreement with Teleost Biopharmaceutic, LLC to acquire various assets for the Company’s proprietary pharmaceutical program segment. The license includes the use of patented small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation. The terms include a \$20,000 fee for signing the agreement and a \$50,000 payment on January 27, 2024. The Company will pay for all new patent costs for new discoveries and new treatments. The Company will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval.

In addition, the Company will make royalty payments on the net sales for commercial products. Beginning in 2025, the Company will also make patent and license maintenance fees.

Competition

There are several drug companies in the US, Europe, India and China that produce generic drugs. Some of the major players are Teva, Sandoz, Hetero, Dr. Reddys, Sun and the list goes on. Very few of the drugs are made by manufacturers in the US and Europe. The quality standards for drugs made in Europe are quite similar to the quality standards mandated by FDA for the US market. The margins made by Chinese and Indian companies selling generics in the US is quite high compared to other markets around the world. There are many reasons for the drug shortages we have experienced in the US for the past 5-6 years. Manufacturing facilities being shut down by FDA, big pharma not being interested in low margin generic drugs, supply chain issues, and only one or two manufacturers remaining after all others have left the marketplace. ANEW has acquired market authorized, approved products in the German market and the Company will apply for FDA approval to market, sell, and distribute these essential medical products in the US as a starting point to build a large portfolio of key medicines that remain in short supply in the US, using either US or European manufacturers.

Biogenetic or biosimilar antibodies are now being approved by the FDA. Pioneering companies like Genentech and Amgen created antibody products that changed the way we treat several diseases. Because of the success of antibody products and now the biosimilar copies of these now “off-patent” antibodies, and the known market needs, there will be competition in all successful product areas. We describe below our plans to differentiate ourselves from others. The “big pharma companies” working in the antibody biosimilars space either grew their efforts in-house due to manufacturing capacity (Sandoz, Amgen and their Activis/Watson acquisition for \$8.5 Billion), Samsung- Bioesis (JV between Samsung Biologics, MSD, and Biogen-Idex for \$1.9 Billion), or through acquisition (Pfizer’s acquisition of Hospira for \$17 Billion, and Teva’s acquisition of Mylan and the Mylan/Biocon JV (\$600M up-front then \$4.5 Billion). Most of the biosimilar companies actually started with the blockbusters recombinant insulins, and migrated to the anti-TNF products named Humira, Embrel and Remicade. There may be 15 or more companies around the world, many in China, with manufacturing capacity for making biosimilars, and most have “followed the dollars” to Humira and the other anti-TNF products. However, in the focused oncology space, we know that companies competing directly with our product oncology portfolio are Sandoz, Amgen/Watson, Mylan/Biocon, Pfizer/Hospira and the Samsung Bioepis JV (Samsung manufactures, and MSD & Biogen-Idex will sell). Thus, ANEW is competing with 5-6 big global pharma companies for Avastin. No new competitors have entered the oncology biosimilars space in the past 4 years. Indian companies include Biocon, Dr. Reddy’s, Intas, and our partner, Reliance Life Sciences (RLS). Most Indian companies are already partnered with U.S. companies (as described above). RLS optimizes manufacturing to show a high degree of analytical biosimilarity and then proves clinical efficacy and comparable safety in randomized clinical studies of nearly 120-150 patients. Thus, following biosimilars guidance and regulations, safety and efficacy is confirmed by RLS before we choose to bring in the products. Specifically, to compete in this market area with oncology and oncology supportive care products, we need to execute on the following initiatives:

1. Incorporate simple improvements. We may incorporate small changes that provide an improvement to the cancer patient and add no additional cost. We can in-license a formulation that allows the drug to remain at room temperature for up to 2 years. This is a simple formulation change with salts and buffers that are “generally-recognized-as-safe” or “GRAS”. The lack of “cold chain” requirement for our biologics will be an improvement for pharmacies and clinics that have to store the product under refrigeration. A formulation that can be given by an injection (subcutaneous) rather than a 1-hour intravenous infusion would make delivery simpler for patients and less expensive to the healthcare system. We have not started to investigate such changes, however some of this altered administration site work has recently been completed by Roche (e.g., to subcutaneous) and is the basis of market approval amendments. Novel formulation and novel delivery systems will be discussed with FDA during the various biosimilar committee meetings with the FDA. Much of this R&D work is proprietary, top secret, and cannot be openly discussed at this time and in this public forum. Our plan is to gain market approval with the basic biosimilar antibody product and research and develop simple and safe alternative methods.
2. Lower generic-like drug pricing. Unlike conventional drugs, biologic drugs take less of a price drop when compared to generic oncology drugs. With the introduction of generic drugs, prices may drop to 80% of the innovator’s original retail price within a year. To date, biosimilar biologics licensed and approved in Europe and the U.S. are only 10-15% below the innovator’s product pricing. Our plan is to price our retail drug pricing 50% below the innovator product and other marketed biosimilars pricing. We can do this because we are only investing in the conduct of Phase 3 trials as our partner (RLS) has funded all product development with the exception of trials powered large enough for FDA and EMA approval. Thus, our return-on-investment (PK/PD and Phase 3) will be realized much sooner than the hundred-of-millions of dollars that other companies must invest to get to the same point – Phase 3. As an example, a 1-gram vial of rituximab (Rituxan) that is sold in the US by Roche/Genentech is currently priced at \$5,000. Our cost-of-goods from RLS is \$200 per 1 gram vial. Therefore, we can launch at \$2,500 per 1 gram vial and the lower margins may attract purchasers because of this significantly lower priced prescription product, allowing ANEW to make a penetration into the marketplace.

3. Hire a technical contract sales organization (CSO). Hundreds of millions of dollars are spent on “in- house” marketing and salespeople. We would have to hire and train a sales force and then continue to pay several million dollars per month to keep the sales force busy, let alone pay for other marketing and sales expenses. Instead, we can keep our burn rate lower and pricing lower by recruiting and hiring a contract sales organization or “CSO”. The CSO can allocate a certain number of salespeople per region that can be trained and deployed, and we only pay for the people and the time spent by the people marketing and educating the market on our products. Outside the U.S., we will have European and Israel partners to submit to Government tender offers and distribute, market, and sell products in countries outside the U.S. Our senior management team has worked for large pharmaceutical companies and can manage the CSO sales force once our products are approved for marketing and sales.

4. Educate the patients/consumers about biosimilars. It is important to educate “the consumer” and physicians on our biosimilar biologics portfolio as a differentiator. Generic drugs are not marketed. There will be a limited amount of marketing for biosimilars as they are well known in the literature, in the clinic, and in regulatory submissions. Once our products are approved for sales, we will have a trained, scientific sales force who will educate the physician, patients, pharmacists and payors (insurance, Governments, etc.) on the clinical data, the similarity results, the pricing differences, and the quality of our product compared to the other companies with product in the biosimilars space. The results showing identical amino acid sequences of our proteins versus the Roche antibodies may be a highlight.

5. Orphan Drug and new indications. Many drugs are approved for one indication, and then the market expanded with additional clinical trials proving efficacy in other indications. The FDA and other regulatory authorities are now allowing “extrapolation”, which means if the Phase 3 study results are equal or within 20% similar to the results of the innovator product results, the biosimilar will be approved for the indication tested in the Phase 3, but also for other indications (diseases) that are covered in the label (the package insert) of the innovator’s product. For example, Herceptin (trastuzumab) is approved for breast cancer and for gastric cancer that over-express the HER-2 oncogene. When a biosimilar to Herceptin is approved based on a Phase 3 study done in metastatic breast cancer, it will be approved through extrapolation to adjuvant breast cancer and for gastric cancer as well. As another example, rituximab (Roche’s Mabthera and Rituxan) is approved to treat B-cell lymphoma, B-cell leukemia, rheumatoid arthritis, and a few other autoimmune diseases as defined in the label (package insert). Autoimmune disease is a very large category of diseases, rare and common, that result in the body making autoantibodies against “self” proteins. The antibodies that attack normal tissues are made by B-cells, and rituximab eliminates B-cells for a time and the disease goes into remission. Ultimately, the B-cells return, and another dose of rituximab is needed. Since there are dozens of autoimmune diseases that are rare, and the rare diseases are of little interest to “big pharma”, we plan on the conduct of studies in rare autoimmune disease and obtain orphan drug designations for our rituximab- ANEW in these rare diseases. Obtaining Orphan Drug designations prevents the off-label use of Mabthera or any biosimilar to rituximab-ANEW in this indication for 7 to 10 years and gives the Company several other beneficial advantages (tax break on all clinical trial costs, waiver on the PDUFA Fees, etc.). We will file for Orphan Drug designation after the start of the PK/PD and Phase 3 clinical trial sponsored by ANEW.

Biosimilar Portfolio Status

Portfolio	Originator – Reference Product Patent Expiry Date	Process Development & Comparability Testing ~18 Month	Pre-Clinical & Clinical ~24 Mo	Clinical PK and Phase 3 ~24 Months from Start	Anticipated BLA Filing Date
Rituximab- -anew	Rituxan® & Mabthera® Genentech Roche US: 2016 EU: 2018	Completed by RLS		Pre-Phase 3 Regulatory meetings with FDA & EMA In Process	US: 2026 EU: 2025
Bevacizumab- -anew	Avastin® Genentech Roche US: 2020 EU: 2022	Completed by RLS		Pre-Phase 3 Regulatory meetings with FDA & EMA In Process	US: 2026 EU: 2025

RLS = Reliance Life Sciences Pvt Ltd
 PK = Pharmacokinetics
 BLA = Biologics License Application under 351(k)

The License Agreement and Manufacturing Agreement with RLS are confidential and will remain confidential during the term of the agreement. ANEW has the exclusive right to develop and commercialize the two biosimilars in our Territories for the term and renewable terms and ANEW has paid \$400,000 in up-front fees to RLS. There are developmental milestone fees to be paid to RLS upon market approvals and a 5% royalty on sales. The Manufacturing Agreement is exclusive to buy active ingredient from RLS during the term and sets forth the bulk antibody purchase price.

A. Summarize the issuer’s business operations (If the issuer does not have current operations, state “no operations”)

Development Stage Company operating in the generic and proprietary medical drug development industry.

B. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of such entity’s business, contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference.

As of December 14, 2020, Dr. Joseph Sinkule is the Company’s sole officer and director.

As of November 1, 2021, ANEW Oncology, Inc. became a wholly owned subsidiary of the Company. ANEW has licensed rights in major world markets to life-saving biologic medicines and gene therapies that will be developed and commercialized by the Company and affiliates and/or corporate partners.

C. Describe the issuers’ principal products or services, and their markets.

Drug development industry.

Item 5. Issuer’s Facilities.

Description of Corporate Offices

The company’s sole officer and director is currently working remotely from his home office at no cost to the issuer until more adequate office space is required.

Item 6. Officers, Directors and Control Persons.

The below table provides information, as of May 15, 2023, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer’s securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Name of Officer/Director or Control Person	Affiliation with Company (e.g., Officer/Director/Owner of more than 5%)	Residential Address (City/State only)	Number of Shares owned	Share type/class	Ownership Percentage of Class Outstanding (1)	Note
Dr. Joseph Sinkule	Chief Executive Officer, Chief Financial Officer and Director	Goodyear, AZ	None 129,501 1,000,000	Common Series B Preferred Series C Preferred	0% 32% 100%	

The below space provides any additional details, including footnotes to the table above:

- As of May 15, 2023, issued and outstanding shares consisted of 1,044,861,360 shares of common stock, 405,205 shares of Series B preferred stock and 1,000,000 shares of Series C preferred stock.

Item 7. Legal/Disciplinary History.

At no time have any of the persons listed above, in the past 10 years, been subject to any of the following:

- A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses).
None
- The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person’s involvement in any type of business, securities, commodities, or banking activities.
None
- A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended or vacated; or
None
- The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person’s involvement in any type of business or securities activities.
None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incident to the business, to which the issuer or any of its subsidiaries is a party or which any of their property is subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceeding known to be contemplated by governmental authorities.

None

Item 8. Third Party Providers

Securities Counsel (Counsel preparing Attorney Letters):

Paul Goodman, Esq.
Cyruli Shanks & Zizmor, LLP
420 Lexington Avenue
Suite 2320
New York, NY 10170
Phone no.: (917) 596-0965
Email: pgoodman@cszlaw.com

Accountant or Auditor:

Rick Basse, CPA
Rick Basse Consulting, PLLC
244 Majestic Oak Drive
New Braunfels, Texas 78132
Phone no.: (210) 347-0374
Email: rick.basse@gmail.com

Investor Relations:

Shawn A. Mesaros
Managing Partner **Ceres BV**
Address: 9B, Atmel Building, 148 Des Voeux Road Central, Central Hong Kong
Phone: (828) 800-8888
Email: sm@ceres.vg

All other means of Investor Communication:

Twitter: None
Discord: None
LinkedIn: None
Facebook: None
[Other] None

Other Service Providers:

The name(s) of other service provider(s), including counsel, advisor(s) or consultant(s) that assisted, advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services to the Company during the Reporting Period are as follows:

Name: None

Firm:

Nature of Services:

Address:

Phone:

Email:

Item 9. Financial Statements.

A. The following financial statements were prepared in accordance with:

- U.S. GAAP
 IFRS

B. The financial statements for this reporting period were prepared by:

Name: Rick Basse, CPA

Title: Owner of Rick Basse Consulting, PLLC

Relationship to Issuer: Accountant engaged by the Company.

The qualifications of the person who prepared the financial statements: The accountant is a CPA licensed by the Texas State Board of Public Accountancy.

The following financial statements described below are provided and incorporated by this reference for the most recent fiscal year or quarter:

- C. Consolidated Balance Sheets;
- D. Consolidated Statements of Operations;
- E. Statement of Changes in Shareholders' Equity
- F. Statement of Cash Flows;
- G. Financial Notes; and
- H. Audit letter, if audited.

Item 10. Issuer's Certifications.

I, Dr, Joseph Sinkule, certify that:

1. I have reviewed the March 31, 2023 Quarterly Report of Strategic Asset Leasing Inc.
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statement, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: May 15, 2023.

Strategic Asset Leasing Inc.



By _____

Dr, Joseph Sinkule, Chief Executive
Officer, Chief Financial Officer and Director

Exhibit A

STRATEGIC ASSET LEASING, INC.
13576 Walnut Street
Omaha, NE 68144

**Financial Statements and Notes
For the Three months Ended March 31, 2023 and 2022**

<u>Contents</u>	<u>Page(s)</u>
<u>Balance Sheets at March 31, 2023 and 2022 (unaudited)</u>	23
<u>Statements of Operations for the three months ended March 31, 2023 and 2022 (unaudited)</u>	24
<u>Statement of Changes in Stockholders' Deficiency for the three months ended March 31, 2023 and 2022 (unaudited)</u>	25
<u>Statements of Cash Flow for the three months ended March 31, 2023 and 2022 (unaudited)</u>	26
<u>Notes to the financial statements</u>	27

STRATEGIC ASSET LEASING, INC.
CONSOLIDATED BALANCE SHEETS (Unaudited)

	March 31, 2023	December 31, 2022
ASSETS		
Current assets:		
Cash	\$ 153,971	\$ 75,872
Prepaid expenses	3,779	3,667
Due from related party	-	250,000
Total current assets	157,750	329,539
Other assets		
Licenses	2,133,750	2,123,750
Patents	86,160	86,160
Total other assets	2,219,910	2,209,910
Total Assets	\$ 2,377,660	\$ 2,539,449
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 23,450	\$ 8,014
Accrued expenses	-	4,742
Note payable	1,347,518	1,347,518
Total current liabilities	1,370,968	1,360,274
Commitments and contingencies	-	-
Stockholders' equity (deficiency):		
Preferred stock Series B, \$0.001 par value; 500,000 shares authorized; 405,250 issued and outstanding as of March 31, 2023 and December 31, 2022	405	405
Preferred stock Series C, \$0.0001 par value; 5,000,000 shares authorized; 1,000,000 issued and outstanding as of March 31, 2023 and December 31, 2022	100	100
Common stock, \$0.0001 par value; 1,500,000,000 shares authorized; 1,044,861,360 issued and outstanding as of March 31, 2023 and December 31, 2022	104,486	104,486
Additional paid in capital	3,539,003	3,539,003
Common stock to be issued	751,400	751,400
Accumulated deficit	(3,388,702)	(3,216,219)
Total stockholders' equity (deficiency)	1,006,692	1,179,175
Total Liabilities and Stockholders' equity	\$ 2,377,660	\$ 2,539,449

The accompanying notes are an integral part of these financial statements.

STRATEGIC ASSET LEASING, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

	For the Three Months Ended	
	March 31, 2023	March 31, 2022
Operating expenses:		
Professional fees	\$ 147,270	\$ 114,850
General and administrative	5,330	8,518
Total operating expenses	152,600	123,368
Net operating income (loss)	(152,600)	(123,368)
Other (income) expense:		
Interest expense	19,936	-
Other (income) expense	(53)	(9)
Total Other (income) expense	19,883	(9)
Net income (loss)	\$ (172,483)	\$ (123,359)
Basic and diluted income (loss) per share	\$ (0.00)	\$ (0.00)
Weighted average number of common shares outstanding - basic	1,044,861,360	1,044,861,360

The accompanying notes are an integral part of these financial statements.

STRATEGIC ASSET LEASING, INC.
CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - Unaudited

	Preferred Stock - Series B		Preferred Stock - Series C		Common Stock		Additional Paid-In Capital	Common Stock to be Issued	Accumulated Deficit	Total Stockholders' Equity (Deficit)
	Shares	Amount	Shares	Amount	Shares	Amount				
<u>Three Months Ended March 31, 2022</u>										
Balance at December 31, 2021	405,250	\$ 405	1,000,000	\$ 100	1,044,861,360	\$ 104,486	\$ 3,539,003	\$ -	(2,617,626)	\$ 1,026,368
Common stock subscription	-	-	-	-	-	-	-	250,000	-	250,000
Net loss, period ended March 31, 2022	-	-	-	-	-	-	-	-	(123,359)	(123,359)
Balance at March 31, 2022	<u>405,250</u>	<u>\$ 405</u>	<u>1,000,000</u>	<u>\$ 100</u>	<u>1,044,861,360</u>	<u>\$ 104,486</u>	<u>\$ 3,539,003</u>	<u>\$ 250,000</u>	<u>\$ (2,740,985)</u>	<u>\$ 1,153,009</u>
<u>Three Months Ended March 31, 2023</u>										
Balance at December 31, 2022	405,250	\$ 405	1,000,000	\$ 100	1,044,861,360	\$ 104,486	\$ 3,539,003	\$ 751,400	(3,216,219)	\$ 1,179,175
Net loss, period ended March 31, 2023	-	-	-	-	-	-	-	-	(172,483)	(172,483)
Balance at March 31, 2023	<u>405,250</u>	<u>\$ 405</u>	<u>1,000,000</u>	<u>\$ 100</u>	<u>1,044,861,360</u>	<u>\$ 104,486</u>	<u>\$ 3,539,003</u>	<u>\$ 751,400</u>	<u>\$ (3,388,702)</u>	<u>\$ 1,006,692</u>

The accompanying notes are an integral part of these financial statements.

STRATEGIC ASSET LEASING, INC.
CONSOLIDATED STATEMENTS OF CASH FLOW (Unaudited)

	For the Three Months Ended	
	March 31, 2023	March 31, 2022
Cash flows from operating activities:		
Net income (loss)	\$ (172,483)	\$ (123,359)
Adjustments to reconcile net loss to net cash used in operating activities:		
Changes in operating assets and liabilities:		
Prepaid expenses	(112)	1,375
Accounts payable	15,436	13,550
Accrued expenses	(4,742)	-
Net cash provided by (used in) operating activities	(161,901)	(108,434)
Cash flows from investing activities:		
Acquisition of drug licenses (See Note 4)	(10,000)	-
Net cash used in investing activities	(10,000)	-
Cash flows from financing activities:		
Proceeds from stock subscriptions	-	250,000
Repayment of advance to shareholder	250,000	-
Net cash provided by financing activities	250,000	250,000
Net increase (decrease) in cash	78,099	141,566
Cash - beginning of the year	75,872	300,853
Cash - end of the year	\$ 153,971	\$ 442,419
Supplemental disclosures:		
Interest paid	\$ 24,678	\$ -
Income taxes	\$ -	\$ -
Supplemental disclosure for non-cash financing activities:		
Acquisition of drugs licenses with a promissory note (See Note 5)	\$ -	\$ -

The accompanying notes are an integral part of these financial statements.

Strategic Asset Leasing, Inc.
Notes to Consolidated Financial Statements
March 31, 2023

NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION

Organization

The accompanying consolidated financial statements include Strategic Asset Leasing, Inc., formerly known as Mammoth Energy Group, Inc. ('LEAS' or the 'Company'), its wholly owned subsidiary and any majority controlling interests.

The Company was incorporated on February 27, 2006, under the laws of the State of Nevada with the aim of pursuing lithium mining. Prior to being domiciled in Nevada, the Company was a Canadian corporation known as Technigen Corporation. In March of 2013, management decided to change the domicile of the Company to Wyoming by filing articles of continuance on March 5, 2013, subsequently dissolving the Nevada corporation.

On December 14, 2020, the Company entered a Stock Purchase Agreement with Dr. Joseph Sinkule for 1,000,000 shares of the Company's Series C preferred stock. The purchase price was \$110,000. Jason Tucker, the Company's CEO, resigned from the Company and Mr. Sinkule became the Company's CEO and sole director.

On November 1, 2021, the Company executed an Agreement and Plan of Merger with Anew Acquisition Corp ("ANEW"), including the wholly own subsidiary ANEW Oncology, Inc., whereby each issued and outstanding share of ANEW common stock was converted into the right to receive one-one hundredth (1/100) of a share of the Company's Series B preferred stock, par value \$.001 per share.

After November 1, 2021, the Company will pursue the development of its licensed rights in major world markets to biologic medicines and gene therapies that will be developed and commercialized by the Company and affiliates and/or corporate partners.

On November 1, 2021, the shareholders of the Company approved a name change to ANEW Medical, Inc. and approved a 1-for-2500 reverse split.

On January 4, 2022, the Company filed an Articles of Amendment with the State of Wyoming, changing its name to "ANEW Medical, Inc." and the contemplated 1-for-2,500 reverse split. During January 2022 and in accordance with SEC Rule 10b-17 and FINRA Rule 6490, the Company submitted documents and other information to FINRA in furtherance of pursuing and obtaining approval of the subject reverse stock split and name change. The Company must submit the additional documents requested by, and necessary to obtain approval of, FINRA in connection with the subject reverse stock split and name change. As of March 31, 2023, the reverse split and name change have not been declared effective.

Business

The Company was formed to develop essential medicines for the treatment of chronic diseases – cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and two proprietary, patented technologies involving the melanocortin receptor-binding molecules and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called "Klotho" inside the body to treat neurodegenerative diseases.

On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany for \$1,386,766. The Market Authorizations (MA's) are for four of the drugs that comprise the "FOLFOX" and "FOLFIRI" multi-drug regimens used in treatment of metastatic colorectal and gastric cancer and in two of the drugs are used to treat metastatic lung cancer. The drugs are important in the treatment of many solid tumors in both childhood and adult cancers. Previously, the Company acquired two off-patent biogeneric antibodies from Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd. of Navi Mumbai, India.

During January 2023, the Company acquired a treatment for small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation for \$20,000.

In accordance with Accounting Standards Codification ("ASC") 915, Development Stage Entities, the Company is considered to be in the development stage, with limited operations since incorporating in the United States.

Summary of Significant Accounting Policies

Basis of Presentation

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America.

Use of Estimates

In preparing financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheet and revenue and expenses in the statement of expenses. Actual results could differ from those estimates.

Reclassifications

Certain prior year amounts have been reclassified for comparative purposes to conform to the current-year financial statement presentation. These reclassifications had no effect on previously reported results of operations. In addition, certain prior year amounts from the restated amounts have been reclassified for consistency with the current period presentation.

Cash and Cash Equivalents

For the purposes of the statement of cash flows, the Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

Concentrations of Risk

Cash and cash equivalents deposited with financial institutions are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company did not hold cash in excess of FDIC insurance coverage at a financial institution as of March 31, 2023 and December 31, 2022.

Prepaid Expenses

The Company considers all items incurred for future services to be prepaid expenses. The prepaid expenses were \$3,779 and \$3,667 at March 31, 2023 and December 31, 2022, consisting of the OTC Market annual fee and pre-paid interest.

Property and equipment

Property and equipment are recorded at cost and depreciated on the straight-line method over the estimated useful lives. Expenditures for normal repairs and maintenance are charged to expense as incurred. The cost and related accumulated depreciation of assets sold or otherwise disposed of are removed from the accounts, and any gain or loss is included in operations.

Licenses/Patents

The Company records the cost to acquire medical license and patents as the initial asset cost.

Upon placing a license in use, licenses are amortized over the useful life.

When the Company files for a patent application, this cost will include the development, writing, generating data, filing and registration, documentation, and other legal fees associated with filing the application and legal costs over years to get the patent to be granted and issued in multiple country markets/regions. Once the patents are approved and in use, and assuming no litigations expenses, the Company amortizes the patent cost over the useful life using the straight-line method. The amortization period will not exceed the lifespan of the protection afforded by the patent. If the expected useful life of the patent is even shorter, the Company will use the useful life for amortization purposes. Thus, the shorter length of a patent's useful life and its legal life will be used for the amortization period.

Valuation of Long-Lived and Intangible Assets

We assess the impairment of long-lived and intangible assets periodically, or at least annually, and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors considered important, which could trigger an impairment review, include the following: significant underperformance relative to historical or projected future cash flows; significant changes in the manner of use of the assets or the strategy of the overall business; and significant negative industry trends. When management determines that the carrying value of long-lived and intangible assets may not be recoverable, impairment is measured as the excess of the assets' carrying value over the estimated fair value. Management is not aware of any other impairment changes that may currently be required; however, we cannot predict the occurrence of events that might adversely affect the reported values in the future.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income. For option-based derivative financial instruments, The Company uses the Black-Scholes option-pricing model to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is reassessed at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.

Fair Value Measurements

In September 2006, the FASB issued ASC 820 (previously SFAS 157) which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The provisions of ASC 820 were effective January 1, 2008.

As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observations of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

The three levels of the fair value hierarchy defined by ASC 820 are as follows:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.

Level 2 – Pricing inputs are other than quoted prices in active markets included in level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors, and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management's best estimate of fair value.

The Company did not identify any assets or liabilities that are required to be adjusted on the balance sheet to fair value as of March 31, 2023 and December 31, 2022.

Revenue Recognition

Revenue is recognized when a customer obtains control of promised goods or services and is recognized in an amount that reflects the consideration that an entity expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods in the contract; (ii) determination of whether the promised goods are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and service transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon delivery.

Income taxes

The Company's policy is to provide for deferred income taxes based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates that will be in effect when the differences are expected to reverse. The U.S. Tax Cuts and Jobs Act (TCJA) legislation reduces the U.S. federal corporate income tax rate from 35.0% to 21.0% and is effective June 22, 2018, for the Company. On January 1, 2023, the U.S. federal corporate income tax increased from 21% to 28%. We did not provide any current or deferred U.S. federal income tax provision or benefit for any of the periods presented because we have experienced operating losses since inception. When it is more likely than not that a tax asset cannot be realized through future income the Company must allow for this future tax benefit. We provided a full valuation allowance on the net deferred tax asset, consisting of net operating loss carryforwards, because management has determined that it is more likely than not that we will not earn income sufficient to realize the deferred tax assets during the carryforward period.

The Company is not aware of any uncertain tax position that, if challenged, would have a material effect on the financial statements for the three-months ended March 31, 2023, or during the prior three years applicable under FASB ASC 740. We did not recognize any adjustment to the liability for uncertain tax position and therefore did not record any adjustment to the beginning balance of accumulated deficit on the consolidated balance sheet. The Company is in the process of filing all unfiled tax returns. All tax returns for the Company remain open for examination.

Basic and diluted net income per share

Basic net loss per common share is computed using the weighted average number of common shares outstanding. Diluted earnings per share (EPS) include additional dilution from common stock equivalents, such as stock issuable pursuant to convertible notes. Common stock equivalents are not included in the computation of diluted earnings per share when the Company reports a loss because to do so would be anti-dilutive for the periods presented. On March 31, 2023 and December 31, 2022, the Company's common stock equivalents consisted of 405,250 shares of Series B preferred stock which may be converted into 40,525,000 shares of the Company's common stock.

Research and Development Cost

Research and development (R&D) costs are expensed as incurred. R&D costs are related to the Company's internally funded development of the Company medical licenses. The Company had R&D costs of \$-0- three months ended March 31, 2023 and 2022.

Stock Compensation

The Company accounts for share-based compensation in accordance with the fair value recognition provisions of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") No. 718 and No. 505. The Company issues restricted stock to employees and consultants for their services. Cost for these transactions are measured at the fair value of the equity instruments issued at the date of grant. These shares are considered fully vested and the fair market value is recognized as an expense in the period granted. The Company recognized consulting expenses and a corresponding increase to additional paid-in-capital related to stock issued for services. For agreements requiring future services, the consulting expense is to be recognized ratably over the requisite service period.

The Company uses the Black-Scholes-Merton valuation model for estimating the fair value of traded options and stock warrants. There were no stock warrants or stock options outstanding on March 31, 2023 and December 31, 2022.

The Company recorded stock-based compensation of \$-0- for the three months ended March 31, 2023, and 2022.

Related Parties

The registrant follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to Section 850-10-20 the Related parties include (a) affiliates of the registrant; (b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of Section 825-10-15, to be accounted for by the equity method by the investing entity; (c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; (d) principal owners of the registrant; (e) management of the registrant; (f) other parties with which the registrant may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and (g) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: (a) the nature of the relationship(s) involved; (b) description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; (c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and (d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

Recently Issued Accounting Standards

Management believes recently issued accounting pronouncements will have no impact on the financial statements of the Company.

NOTE 2 - GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred material recurring losses from operations. The Company has not generated material revenues since inception and has generated losses totaling \$3,388,702 since inception.

The consolidated financial statements do not contain any adjustments to reflect the possible future effects on the classification of assets or the amounts and classification of liability that may result should the Company be unable to continue as a going concern.

NOTE 3 – SEGMENT DATA

The Company has three reportable segments, which it believes best reflect how the Company is currently managed – Generic Drugs, Gene Therapy and Pharmaceutical Programs. The Generic Drugs segment consists of operations focused on bringing various generic drugs to market primarily in the U.S. and Europe markets. The Gene Therapy segment uses a gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases. The Pharmaceutical Programs segment consists of treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The assets of the segments consist of the following at March 31, 2023 and December 31, 2022:

	March 31, 2023	December 31, 2022
Generic drugs:		
Licenses	\$ 2,123,750	\$ 2,123,750
Gene therapy:		
Patents	86,160	86,160
Pharmaceutical programs:		
Licenses	10,000	-
Total	\$ 2,219,910	\$ 2,209,910

The following table presents the Company’s reportable segment results for the three months ended March 31, 2023 and 2022:

	March 31, 2023	March 31, 2022
Revenues:		
Generic drugs	\$ -	\$ -
Gene therapy	-	-
Pharmaceutical programs	-	-
Total	-	-
Expenses:		
Generic drugs	100,763	123,359
Gene therapy	61,720	-
Pharmaceutical programs	12,500	-
Total	172,483	123,359
Net loss:		
Generic drugs	(100,763)	(123,359)
Gene therapy	(61,720)	-
Pharmaceutical programs	-	-
Total	\$ (172,483)	\$ (123,359)

NOTE 4 – LICENCES AND PATENTS

Licenses

During 2015, the Company acquired two licenses two licensed platform technologies, a biosimilar biologics platform that uses biologic therapies to treat cancer – recombinant antibodies, and a gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called “Klotho” inside the body to treat neurodegenerative diseases. The licenses were valued at \$736,983. The licenses are not in use and will be amortized over the useful life.

On January 27, 2023, the Company signed a License Agreement with Teleost Biopharmaceutic, LLC to acquire various assets for the Company’s proprietary pharmaceutical program segment. The license includes the use of patented small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation. The terms include a \$20,000 fee for signing the agreement and a \$50,000 payment on January 27, 2024. The Company will pay for all new patent costs for new discoveries and new treatments. The Company will make standard commercial development-based milestone payments for the various stages of license development and regulatory approval.

In addition, the Company will make royalty payments on the net sales for commercial products. Beginning in 2025, the Company will also make patent and license maintenance fees.

The total licenses were \$2,133,750 and \$2,123,750 at March 31, 2023 and December 31, 2022, respectively, in the accompanying consolidated balance sheet. The licenses are not in use. Once the licenses are in use, the licenses will be amortized over the useful life.

Patents

The Company is filing for patents for Alzheimer, ALS and other items. As of March 31, 2023, the patents have not been finalized. Once the patents are declared effective, the Patents will be amortized over the shorter of a patent's useful life and its legal useful life. The patent cost incurred as of March 31, 2023 and December 31, 2022 was \$86,160 and reported as patents in the accompanying consolidated balance sheet.

NOTE 5 – NOTES PAYABLE

On September 12, 2022, the Company issued a \$1,347,518 promissory note to acquired five market-approved anti-cancer drugs. See Note 4 – Licenses and Patents for a further discussion. The promissory note bear interest at 6% and a maturity date of June 30, 2023. The Company has agreed to make a monthly interest payment of \$6,541. At March 31, 2023 and Company made interest payments of \$19,624. The unpaid balance principal balance was \$1,347,518 at March 31, 2023.

NOTE 6 – EQUITY TRANSACTIONS

The Company was established with three classes of stock, common stock – 1,500,000,000 shares authorized at a par value of \$0.0001 Class B preferred stock 500,000 shares authorized at a par value of \$0.001 and Class C preferred stock 5,000,000 shares authorized at a par value of \$0.0001.

On March 31, 2023 and December 31, 2022, the Company issue and outstanding common stock was 1,044,861,360 shares, 405,250 shares of Class B preferred stock and 1,000,000 shares of Class C preferred stock.

On November 1, 2021, the shareholders of the Company approved a 1-for-2500 reverse split. As of March 31, 2023, the reverse split has not been declared effective.

On February 21, 2022, the Company entered into a Stock Purchase Agreement with an individual to sell 1,666,667 shares of the Company's common stock for \$250,000 or \$0.15 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of March 31, 2023. The shares have not been issued to the individual at March 31, 2023.

On September 12, 2022, the Company entered into a Stock Purchase Agreement with an individual to sell 2,000,000 shares of the Company's common stock for \$500,000 or \$0.25 shares. The shares issued will be calculated on a post-reverse split basis. The Company has a planned 1-for-2500 reverse stock split of its common stock was not declared effective as of March 31, 2023. The shares have not been issued to the individual at March 31, 2023.

NOTE 7 – MATERIAL CONTRACTS

On November 27, 2014, the Company signed a License Agreement and a Manufacturing and Supply Agreement for the monoclonal antibody development license and supply agreement and related manufacturing with Reliance Life Sciences (RLS), the life science arm of Reliance Industries Pvt Ltd, the largest private company in India. The contract expires on November 27, 2024 with a 10-year renewal option. The License Agreement entitles the Company to pay \$100,000 per product for a total of three products with milestone payments for meeting certain criteria. In addition, the Company will pay a quarterly royalty payment of 5% on net sales of finished products. The Manufacturing and Supply Agreement contains an estimated acquisition price of active pharmaceutical ingredients (API) of \$350,000 per Kg for each product developed. As of March 31, 2023, the Company has not generated any activity under the agreement.

On October 1, 2020, the Company entered into a three-year Management Consulting Services Agreement with an individual to provide various services including raising funds for the Company. The contact terminates on September 30, 2023. The consultant is compensated with 3% of the net proceeds of the any contractual relationship and equity compensation of up to 3% of the value of the business development contract with restricted share of the Company's common stock. As of March 31, 2023, the Company has not generated any activity under the agreement.

On October 10, 2021, the Company signed an Employment Agreement with Dr, Joseph Sinkule to serve as the Company's CEO for three years ending on October 9th 2024. In addition, My Sinkule will serve as a member of the board of directors for a five-year term. Mr. Sinkule's Quarterly salary will be \$240,000 per year and increase to \$360,000 per year upon raising a total of five million dollars (\$5,000,000) or more in equity and/or debt financing.

On November 19, 2021, the Company sign a consulting agreement with an individual to raise capital for new medical products and commercialize such products for a 5% commission fee. As of March 31, 2023, the Company has not generated any activity under the agreement.

On January 24, 2022, the Company signed an exclusive, world-wide License Agreement with the University of Barcelona for a cell and/or gene therapy that has shown compelling activity in animal models of human Alzheimer’s disease and amyotrophic lateral sclerosis (“ALS” or “Lou Gehrig’s disease”). The gene therapy will also be applied to age-related diseases and rare (“Orphan”) diseases. Beginning on December 15, 2022, the Quarterly license fee is 10,000 Euros. In addition, the Company will pay a Royalty equal to 3% of net sales of finished products. For the three months and three months ended March 31, 2023, respectively, the Company has spent \$-0- under the agreement.

On April 5, 2022, the Company entered into a Business Development and Consulting Agreement with an individual to serve as the Company’s chief business officer. Beginning on May 1, 2022, the consultant is compensated with \$10,000 a month for the three months ended July 31, 2022 and \$15,000 thereafter. The consultant works approximately 80 hours a month. In addition to cash considerations, the consultant was compensated with 1,000,000 shares of the Company’s common stock valued at \$1,400 or \$0.0014 per share. As of March 31, 2023, the shares have not been issued to the consultant. During the three months ended March 31, 2023 and 2022, the consultant was paid \$-0-. The Contract was terminated on August 15, 2022 with no amount due to the consultant.

On October 19, 2022, the Company sign a M&A/Capital Markets Advisory Agreement with a firm to advise and assist the Company in negotiating the terms and conditions with respect to a potential sale, purchase, merger, joint venture, business combination, material change of control, or similar transaction involving the Company and a strategic acquirer and/or private or publicly listed entity or business, including a Special Purpose Acquisition Company (SPAC), and with respect to any offerings of any equity, equity-linked or debt securities of the Company or any other party to a financing transaction and perform such other financial advisory services to the Company. The Company will compensate the firm with an M&A fee, a financing fee and expenses.

Upon consummation of a transaction, the Company will pay the firm an M&A fee consisting of an aggregate of a sum equal to the greater of \$2,500,000 or the sum of the following amounts:

- four percent (4.0%) of the first \$100 MM of Aggregate Value;
- three percent (3.0%) of any amount of the Aggregate Value between \$100 MM and \$200 MM;
- two percent (2.0%) of any amount of the Aggregate Value between \$200 MM and \$300MM;
- one percent (1.0%) of any amount of the Aggregate Value exceeding \$300 MM

In addition, the Company will pay the firm a financing fee of seven percent (7%) of the aggregate amount of proceeds received from investors in the financing of any equity or equity-linked securities and three percent (3%) of the aggregate amount of proceeds received from the Financing of any non-equity-linked debt securities and credit facilities.

NOTE 8 – RELATED PARTIES

During November 2022, the Company advanced a shareholder \$300,000 as a short-term loan. The loan is non-interest bearing and due by the end of December 2022. The shareholder repaid \$50,000 during December 2022 and \$250,000 in January 2023 to fully satisfy the advance. At March 31, 2023 and December 31, 2022, the loan balance was \$-0- and \$250,000, respectively and is reported in due from related party in the accompanying consolidated balance sheets.

NOTE 9 – SUBSEQUENT EVENTS

The Company evaluated all events or transactions that occurred through May 15, 2023. During this period, the Company did not have any material recognizable subsequent events.